Takayasu Arteritis (TAK) is a large-vessel vasculitis that preferentially involves the aorta and
its primary branches. Cardiac involvement is frequent in TAK and is a major determinant of …

Background—The goal of this work was to assess the safety and efficacy of biologics (ie,
tumor necrosis factor-α antagonists and tocilizumab) in patients with Takayasu arteritis …

The objective of this study was to report the long-term use of tumor necrosis factor (TNF)
inhibitors in case series of patients with Takayasu's arteritis refractory to standard …

Objective This study aims to evaluate the effectiveness and safety of adalimumab (ADA)
compared with leflunomide (LEF) in patients with Takayasu arteritis (TAK). Method A …

Objective To compare the treatment outcomes of TNF inhibitors and tocilizumab (TCZ) in
patients with Takayasu arteritis. Methods Takayasu arteritis patients who were refractory to …

Takayasu arteritis (TA) is a chronic inflammatory disease of large arteries which
progressively develop stenosis, occlusion or aneurismal degeneration. Proinflammatory …

Objective To report a single‐center experience with the use of tumor necrosis factor (TNF)
inhibitors in patients with Takayasu arteritis (TA). Methods We retrospectively studied a …

Takayasu arteritis (TA) is a true orphan disease. There are no published controlled clinical
trials and the evidence on which to develop management strategies and therapeutic …

Objective This study aimed to compare the efficacy and safety of adalimumab (ADA) vs
tocilizumab (TCZ) in patients with Takayasu arteritis (TAK). Methods This was a randomized …

DEAR EDITOR, The recent trial comparing adalimumab with tocilizumab in patients with
severe, active Takayasu arteritis (TAK) addresses an important research question [1]. The …